NFlection Therapeutics

NFlection Therapeutics

  • Founded: 2014
  • Location: Wayne, PA
  • Employee range: 1 - 10
  • Clinical stage: Clin1
  • Therapy area: Neurofibromatosis type 1
  • Drug types: GEN, DRM, ONC
  • Lead product: NFX-179
  • Product link: https://nflection.com/pipeline
  • Funding: $20M A Jun 2020
  • Investors: venBio partners, F-Prime Capital


nflection.com

linkedin.com


Short description:

Development of  therapies for Neurofibromatosis 1

Drug notes:

Also Clin0 congenital birthmarks, RD/Clin0 squamous cell carcinoma

Long description:

NFlection Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel topical treatments for rare dermatological disorders that involve dysfunction in the RAS pathway. RAS proteins play a crucial role in cell growth and signaling. NFlection utilizes mitogen-activated protein kinase kinase (MEK) inhibitors to target a key protein in the RAS signaling pathway in order to halt the growth of abnormal cells. Formulating these inhibitors as topical gels allows for convenient and localized treatment, circumventing systemic side effects that come with oral or injectable drugs. These topical treatments could help patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks.

Jobs:


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com